EUCTR2022-001091-34-EE招募中1 期
A double blind, randomized, placebo-controlled trial evaluatingthe efficacy and safety of BI 1015550 over at least 52 weeks inpatients with Idiopathic Pulmonary Fibrosis (IPF) - PDE4 Phase III trial in IPF (Fibroneer- IPF)
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 入组人数
- 963
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •Patients =40 years old at the time of signed consent
- •IPF diagnosis based on 2022 ATS/ERS/JRS/ALAT Guidelines
- •FVC =45% of predicted normal
- •DLCO =25% predicted of normal corrected for hemoglobin
- •On stable treatment with nintedanib or pirfenidone for at least
- •12 weeks or not on treatment with either nintedanib or
- •pirfenidone for at least 8 weeks
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 337
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 626
排除标准
- •Prebronchodilator FEV1/FVC <0.7
- •Acute IPF exacerbation within 3 months and/or during the screening period
- •Treated with immunomodulatory medications (other than oral
- •corticosteroids) or prednisone >15 mg/day or equivalent for
- •respiratory or pulmonary reasons
- •Active, unstable or uncontrolled vasculitis within 8 weeks
- •Any suicidal behaviour in the past 2 years
- •Any suicidal ideation of type 4 or 5 on the C-SSRS in the past 3 months
研究者
相似试验
已完成
3 期
A study to find out whether BI 1015550 improves lung function in people with Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs)2024-512803-37-00Boehringer Ingelheim International GmbH, Boehringer Ingelheim Espana S.A.303
进行中（未招募）
1 期
Efficacy and safety of nintedanib in patients with PF-ILDThe aim of the current study is to investigate the efficacy and safety of 150 mg bid nintedanib over 52 weeks in patients with Progressive Fibrosing Interstitial Lung Disease (PF-ILD) defined as patients who present with features of diffuse fibrosing lung disease of >10% extent on high-resolution computed tomography (HRCT) and whose lung function and respiratory symptoms or chest imaging have worsened despite treatment with unapproved medications used in clinical practice to treat ILD.EUCTR2015-003360-37-BESCS Boehringer Ingelheim Comm. V600
进行中（未招募）
3 期
A study to find out whether BI 1015550 improves lung function in people with Idiopathic Pulmonary Fibrosis (IPF)Idiopathic Pulmonary FibrosisJPRN-jRCT2031220317Saito Isao963
招募中
1 期
A study to find out whether BI 1015550 improves lung function in people with Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs)Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs)MedDRA version: 23.1Level: LLTClassification code 10084309Term: Progressive fibrosing interstitial lung diseaseSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersEUCTR2022-001134-11-DKBoehringer Ingelheim B.V.1,041
招募中
1 期
A study to find out whether BI 1015550 improves lung functionin people with Idiopathic Pulmonary Fibrosis (IPF)EUCTR2022-001091-34-SEBoehringer Ingelheim AB963